MA34004B1 - Protéines de liaison à cd127 - Google Patents

Protéines de liaison à cd127

Info

Publication number
MA34004B1
MA34004B1 MA35147A MA35147A MA34004B1 MA 34004 B1 MA34004 B1 MA 34004B1 MA 35147 A MA35147 A MA 35147A MA 35147 A MA35147 A MA 35147A MA 34004 B1 MA34004 B1 MA 34004B1
Authority
MA
Morocco
Prior art keywords
antigen binding
binding proteins
protein link
diseases
protein
Prior art date
Application number
MA35147A
Other languages
Arabic (ar)
English (en)
Inventor
Ian Kirby
Alexander H Taylor
Thomas Matthew Webb
Yu Xue
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA34004B1 publication Critical patent/MA34004B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

L'invention concerne des protéines de liaison à un antigène qui se lient au récepteur humain de l'IL-7 (CD127). Les protéines de liaison à un antigène sont typiquement des anticorps, et sont utiles dans le traitement de maladies ou de troubles chez les êtres humains, particulièrement de maladies auto-immunes telles que la sclérose en plaques.
MA35147A 2010-01-28 2011-01-26 Protéines de liaison à cd127 MA34004B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29901010P 2010-01-28 2010-01-28
PCT/US2011/022507 WO2011094259A2 (fr) 2010-01-28 2011-01-26 Protéines de liaison à cd127

Publications (1)

Publication Number Publication Date
MA34004B1 true MA34004B1 (fr) 2013-02-01

Family

ID=44320081

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35147A MA34004B1 (fr) 2010-01-28 2011-01-26 Protéines de liaison à cd127

Country Status (25)

Country Link
US (2) US9150653B2 (fr)
EP (1) EP2528947A4 (fr)
JP (1) JP5850860B2 (fr)
KR (1) KR20130028055A (fr)
CN (1) CN102812046B (fr)
AR (1) AR080027A1 (fr)
AU (1) AU2011209713B2 (fr)
BR (1) BR112012018914A2 (fr)
CA (1) CA2787070A1 (fr)
CL (1) CL2012002081A1 (fr)
CO (1) CO6592067A2 (fr)
CR (1) CR20120404A (fr)
EA (1) EA023700B1 (fr)
IL (1) IL220899A (fr)
MA (1) MA34004B1 (fr)
MX (1) MX339083B (fr)
MY (1) MY160590A (fr)
NZ (1) NZ601271A (fr)
PE (2) PE20121702A1 (fr)
SG (1) SG182590A1 (fr)
TW (1) TWI489996B (fr)
UA (1) UA104663C2 (fr)
UY (1) UY33202A (fr)
WO (1) WO2011094259A2 (fr)
ZA (1) ZA201205624B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865068T3 (es) 2011-01-14 2021-10-14 Univ California Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
EP2583980A1 (fr) * 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
EP2955196A1 (fr) * 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
WO2016059512A1 (fr) 2014-10-18 2016-04-21 Pfizer Inc. Compositions d'anticorps anti-il-7r
WO2017055966A1 (fr) 2015-10-01 2017-04-06 Pfizer Inc. Compositions d'anticorps à faible viscosité
AU2017205185B2 (en) * 2016-01-07 2022-03-31 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
CA3014313A1 (fr) * 2016-02-29 2017-09-08 Ose Immunotherapeutics Anticorps non antagonistes diriges contre la chaine alpha du domaine extracellulaire du recepteur de l'il-7 et son utilisation dans le traitement du cancer
HUE054206T2 (hu) * 2016-12-09 2021-08-30 Ose Immunotherapeutics A CD127 ellen irányított antitestek és polipeptidek
AU2020210635A1 (en) * 2019-01-22 2021-08-19 Bristol Myers Squibb Company Antibodies against IL-7R alpha subunit and uses thereof
JP2022538083A (ja) 2019-06-21 2022-08-31 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
WO2020254828A1 (fr) 2019-06-21 2020-12-24 Vhsquared Limited Compositions
CA3144567A1 (fr) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
WO2023232826A1 (fr) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarqueurs de l'activité du modulateur de l'il7r
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
CA2033082A1 (fr) * 1989-06-15 1990-12-16 Linda S. Park Recepteurs de l'interleukine 7
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1993006213A1 (fr) 1991-09-23 1993-04-01 Medical Research Council Production d'anticorps chimeriques - une approche combinatoire
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
WO1994004690A1 (fr) 1992-08-17 1994-03-03 Genentech, Inc. Immunoadhesines bispecifiques
ES2138662T3 (es) 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
WO1996021000A2 (fr) * 1994-12-23 1996-07-11 Smithkline Beecham Corporation Antagonistes de recombinaison de l'il-5 utiles dans le traitement des troubles induits par l'il-5
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1997042329A1 (fr) * 1996-05-04 1997-11-13 Zeneca Limited Anticorps monoclonal anti-cea, conjugues contenant cet anticorps et leur utilisation therapeutique dans un systeme adept
PL335050A1 (en) 1997-02-07 2000-03-27 Merck & Co Inc Synthetic genes gag hiv
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MXPA01010296A (es) * 1999-04-13 2005-06-30 Wilex Ag Diagnostico y uso terapeutico de anticuerpos contra el receptor urocinasa.
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2003011878A2 (fr) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
ATE541857T1 (de) 2002-09-27 2012-02-15 Xencor Inc Optimierte fc-varianten und herstellungsverfahren dafür
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005003156A1 (fr) 2003-07-04 2005-01-13 Affibody Ab Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2)
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1711196A4 (fr) 2003-12-05 2011-09-14 Bristol Myers Squibb Co Inhibiteurs des recepteurs du facteur de croissance endothelial vasculaire de type 2
EP1776385A1 (fr) 2004-07-21 2007-04-25 Glycofi, Inc. Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2
WO2006052660A2 (fr) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Blocage du recepteur il-7 pour supprimer l'immunite
US7935791B2 (en) 2006-12-18 2011-05-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
BRPI0906498A2 (pt) * 2008-01-22 2015-07-14 Biogen Idec Inc Anticorpo ron e seus usos
UY32038A (es) * 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos

Also Published As

Publication number Publication date
AR080027A1 (es) 2012-03-07
US20120282254A1 (en) 2012-11-08
CR20120404A (es) 2012-10-04
US20110200585A1 (en) 2011-08-18
CL2012002081A1 (es) 2012-12-14
IL220899A0 (en) 2012-09-24
IL220899A (en) 2017-08-31
PE20170687A1 (es) 2017-06-13
EP2528947A2 (fr) 2012-12-05
AU2011209713B2 (en) 2014-04-03
EA023700B1 (ru) 2016-07-29
WO2011094259A2 (fr) 2011-08-04
CN102812046B (zh) 2015-02-25
CO6592067A2 (es) 2013-01-02
US8940303B2 (en) 2015-01-27
SG182590A1 (en) 2012-08-30
UA104663C2 (en) 2014-02-25
EP2528947A4 (fr) 2013-09-18
CN102812046A (zh) 2012-12-05
AU2011209713A1 (en) 2012-09-13
NZ601271A (en) 2014-09-26
JP5850860B2 (ja) 2016-02-03
EA201290589A1 (ru) 2013-05-30
TWI489996B (zh) 2015-07-01
ZA201205624B (en) 2014-01-29
MX339083B (es) 2016-04-01
CA2787070A1 (fr) 2011-08-04
PE20121702A1 (es) 2012-12-14
UY33202A (es) 2011-08-31
WO2011094259A3 (fr) 2011-09-29
JP2013517799A (ja) 2013-05-20
TW201136607A (en) 2011-11-01
KR20130028055A (ko) 2013-03-18
BR112012018914A2 (pt) 2017-07-25
MY160590A (en) 2017-03-15
MX2012008765A (es) 2012-09-07
US9150653B2 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
MA34004B1 (fr) Protéines de liaison à cd127
PH12014502527B1 (en) St2 antigen binding proteins
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12013502205A1 (en) Antibodies to il-6 and their uses
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
WO2014114651A9 (fr) Protéines de liaison à l'antigène tnf-alpha
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
UA112416C2 (uk) Антитіло до fap і способи його застосування
MX336196B (es) Proteinas de union a amiloide beta.
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX343659B (es) Proteínas de unión receptoras fc.
MX2020003503A (es) Proteinas de union al antigeno del receptor de oncostatina m.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
EA201590918A1 (ru) Антитела к bmp-6
MX360163B (es) Moleculas de union il-6.
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
WO2011116212A3 (fr) Agents de liaison de récepteur de protéine morphogénétique osseuse et procédés de leur utilisation
MY149448A (en) Interleukin-21 receptor binding proteins